The Roles of EXO1 and RPA1 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Table 1

The 19 single nucleotide polymorphisms examined in this study.

Gene	SNPs	Alleles	MAF	Call rates (%)
EXO1	rs1047840	G/AC	0.35	97.03
EXO1	rs1776148	A/GT	0.32	97.78
EXO1	rs735943	A/G	0.36	97.78
PMS1	rs5742933	G/AC	0.22	96.30
PMS2	rs1062372	C/AGT	0.23	95.56
PMS2	rs2228006	T/ACG	0.12	99.01
RPA1	rs17292622	G/AT	0.22	98.84
RPA1	rs17339382	G/A	0.09	92.28
RPA1	rs3744768	G/A	0.20	98.55
RPA1	rs12727	G/C	0.24	98.26
RPA1	rs17339395	G/ACT	0.22	98.55
RPA1	rs9914073	A/CG	0.23	98.26
RPA1	rs9082	T/C	0.23	98.84
RPA1	rs3744766	C/G	0.22	98.84
RPA1	rs1131636	C/AGT	0.46	98.84
RPA1	rs5030740	C/AGT	0.30	99.42
RPA1	rs3744767	T/C	0.24	99.42
RPA1	rs3744769	C/AGT	0.22	97.69
RPA1	rs17734	C/T	0.43	99.42

MAF: minor allele frequency.